

Editorial



Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Are Beta-Blockers Still Relevant?

Junho Hyun , MD, MSc

Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

► See the article “Differences in the Effects of Beta-Blockers Depending on Heart Rate at Discharge in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation” in volume 6 on page 119.

OPEN ACCESS

Received: Jul 14, 2024

Accepted: Jul 16, 2024

Published online: Jul 18, 2024

Correspondence to


Junho Hyun, MD, MSc

Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea.
Email: jhhyun0609@gmail.com

Copyright © 2024. Korean Society of Heart Failure

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Junho Hyun 

<https://orcid.org/0000-0003-4211-3081>

Conflict of Interest

The author has no financial conflicts of interest.

While the efficacy of beta-blockers (BBs) in patients with heart failure (HF) with reduced ejection fraction is well-established,¹⁻³ the evidence supporting their use in patients with heart failure with preserved ejection fraction (HFpEF) is limited. Conceptually, heart rate (HR) reduction is believed to benefit patients as it increases ventricular filling time.⁴ However, numerous studies have failed to demonstrate the benefits of HR reduction in patients with HFpEF.^{5,6} Conversely, chronotropic incompetence is considered a major pathophysiologic mechanism in HFpEF,⁷ and BBs can worsen symptoms and exercise capacity. Moreover, there is evidence that increasing HR through atrial pacing in an HFpEF population can reduce left ventricular end-diastolic filling pressure.⁸ Furthermore, BBs in HFpEF can worsen exercise capacity, which can be reversed after withdrawing BBs.^{9,10}

The effects of BBs on clinical outcomes in patients with HFpEF remain unclear. One major factor contributing to this uncertainty is the lack of large-scale, randomized controlled trials targeting patients with HFpEF treated with BBs. In the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure (SENIORS) trial, approximately 36% of enrolled patients had left ventricular ejection fraction (LVEF) greater than 35%, and post-hoc analysis suggested a potential association between nebivolol use and improved LVEF.¹¹ However, many of these patients met the HF category of mildly reduced LVEF, limiting the findings' applicability to true HFpEF populations and failing to demonstrate improved clinical outcome. A meta-analysis of patients with LVEF greater than 40% also found no evidence that BBs improved clinical outcomes.¹²

Atrial fibrillation (AF) is common in HFpEF, and doubles the risk of mortality, serving as a poor prognostic marker.¹³ However, few studies have explored the efficacy of BBs in patients with HFpEF and AF. In this issue of the *International Journal of Heart Failure*, Kim et al.¹⁴ analyzed 687 patients from the Korean Acute Heart Failure (KorAHF) registry, who were hospitalized with acute HF and presented with LVEF \geq 50% and concomitant AF. The study divided patients into high and low HR groups based on a median heart rate of 75 bpm and analyzed outcomes based on BBs prescription at discharge. While no difference was observed in the low HR group, the high HR group showed notably reduced rehospitalization events with BB use. Although studies on BBs in HFpEF with AF are scarce, some retrospective studies have reported improved clinical outcome with BBs.^{15,16}

The strength of the study is the highlight of the differential effects of BBs based on HR in patients with AF. A prior study using KorAHF registry demonstrated reduced rehospitalization risk in patients with HFpEF and AF,¹⁷⁾ and the current study may suggest a potential mechanism and specific subgroup among the HFpEF and AF population regarding BBs benefit. The finding that BBs use reduced HF rehospitalization in patients with high HR suggests that tachycardia may be an important mechanism of HF worsening in this population. Another interesting aspect in this study is that among patients with low HR, HR was inversely correlated with increased rehospitalization risk with BBs, possibly due to bradycardia or exaggerated chronotropic incompetence, consistent with previous studies.

The limitations of this study include, change in more than 40% of BB prescriptions after discharge, lack of consistent benefit in long-term period, and missing data on rhythm control strategy. According to recent findings from the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4), the presence of rhythm control therapies could be a major confounding factor.¹⁸⁾ Nevertheless, maintaining an appropriate HR range in patients with HFpEF with AF underscores the importance of managing this comorbid condition effectively. Recent analyses of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial suggested a potential beneficial role of BBs in the specific clinical scenario of AF in HFpEF.¹⁹⁾ Future large-scale prospective studies and meta-analyses are warranted to validate potential roles of BBs and the adequate range of HR for these specific patients with HFpEF and AF.

REFERENCES

- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2022;145:e895-1032. [PUBMED](#) | [CROSSREF](#)
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599-726. [PUBMED](#) | [CROSSREF](#)
- Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. *Int J Heart Fail* 2023;5:66-81. [PUBMED](#) | [CROSSREF](#)
- Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. *N Engl J Med* 1985;312:277-83. [PUBMED](#) | [CROSSREF](#)
- Silverman DN, Plante TB, Infeld M, et al. Association of β -blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. *JAMA Netw Open* 2019;2:e1916598. [PUBMED](#) | [CROSSREF](#)
- Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). *Eur J Heart Fail* 2013;15:110-8. [PUBMED](#) | [CROSSREF](#)
- Rosano GM, Vitale C, Spoletini I. Precision cardiology: phenotype-targeted therapies for HFmrEF and HFpEF. *Int J Heart Fail* 2024;6:47-55. [PUBMED](#) | [CROSSREF](#)
- Meyer M, LeWinter MM. Heart rate and heart failure with preserved ejection fraction: time to slow β -blocker use? *Circ Heart Fail* 2019;12:e006213. [PUBMED](#) | [CROSSREF](#)
- Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. *Eur J Heart Fail* 2012;14:219-25. [PUBMED](#) | [CROSSREF](#)
- Palau P, Seller J, Dominguez E, et al. Effect of β -blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. *J Am Coll Cardiol* 2021;78:2042-56. [PUBMED](#) | [CROSSREF](#)
- van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). *J Am Coll Cardiol* 2009;53:2150-8. [PUBMED](#) | [CROSSREF](#)
- Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. *Eur Heart J* 2018;39:26-35. [PUBMED](#) | [CROSSREF](#)
- Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. *Circulation* 2013;128:1085-93. [PUBMED](#) | [CROSSREF](#)
- Kim YI, Ahn MS, Yoo BS, et al. Differences in the effects of beta-blockers depending on heart rate at discharge in patients with heart failure with preserved ejection fraction and atrial fibrillation. *Int J Heart Fail* 2024;6:120-7. [CROSSREF](#)
- Yang Y, Guo S, Huang Z, et al. Decreased mortality with beta-blocker therapy in HFpEF patients associated with atrial fibrillation. *Cardiol Res Pract* 2020;2020:3059864. [PUBMED](#) | [CROSSREF](#)
- Lam PH, Gupta N, Dooley DJ, et al. Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate. *Am J Med* 2018;131:1473-81. [PUBMED](#) | [CROSSREF](#)
- Ahn MS, Yoo BS, Son JW, et al. Beta-blocker therapy at discharge in patients with acute heart failure and atrial fibrillation. *J Korean Med Sci* 2020;35:e278. [PUBMED](#) | [CROSSREF](#)
- Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. *Circulation* 2021;144:845-58. [PUBMED](#) | [CROSSREF](#)
- Peikert A, Bart BA, Vaduganathan M, et al. Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial. *JACC Heart Fail* 2024;12:631-44. [PUBMED](#) | [CROSSREF](#)